文献速递临床试验与 GCP

托珠单抗对接受糖皮质激素治疗的活动性风湿性多肌痛患者疾病活动度的影响:一项随机临床试验

Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

这项在法国17家医院开展的双盲、平行组、安慰剂对照随机临床试验纳入101例糖皮质激素依赖性活动性风湿性多肌痛患者,比较托珠单抗与安慰剂联合标准化泼尼松减量方案的疗效。第24周时,托珠单抗组达到主要终点(CRP PMR-AS<10且泼尼松≤5 mg/日或较基线下降≥10 mg)的比例为67.3%,安慰剂组为31.4%(校正差值36.0%[95%CI 19.4%-52.6%],校正相对危险度2.3[95%CI 1.5-3.6],P<.001)。

要点

  • 托珠单抗组第24周主要终点达标率67.3%,安慰剂组31.4%,校正相对危险度2.3(95%CI 1.5-3.6)。
  • 托珠单抗组平均CRP PMR-AS评分为7.5(95%CI 5.4-9.6),安慰剂组为14.9(95%CI 11.4-18.4),校正差值-7.5(95%CI -11.2至-3.8)。
  • 托珠单抗组49.0%患者不再使用泼尼松,安慰剂组为19.6%,校正相对危险度2.5(95%CI 1.8-3.5)。

核心结论

  • 在尽管接受泼尼松治疗仍处于活动期的风湿性多肌痛患者中,与安慰剂相比,托珠单抗使第24周达到CRP PMR-AS<10且泼尼松需求减少的患者比例显著更高。
  • 需要进一步研究以确认疗效并确定潜在获益与危害的平衡。

研究设计与样本

  • 双盲、平行组、安慰剂对照随机临床试验,纳入101例风湿性多肌痛患者,来自法国17家医院,入组时间为2017年2月至2019年10月,最终随访于2020年11月完成。
  • 纳入标准为持续疾病活动(使用C反应蛋白水平计算的风湿性多肌痛活动度评分[CRP PMR-AS]>10)且泼尼松剂量≥10 mg/日。
  • 患者随机接受静脉托珠单抗(8 mg/kg;n=51)或安慰剂(n=50),每4周一次,共24周,联合预设的标准化口服泼尼松减量方案。
  • 101例随机患者中,平均年龄67.2岁,女性68例(67.3%),100例(99%)接受至少1次输注,100例完成试验。

主要发现

  • 主要终点(第24周CRP PMR-AS<10且泼尼松剂量≤5 mg/日或较基线下降≥10 mg)在托珠单抗组达到67.3%,安慰剂组为31.4%(校正差值36.0%[95%CI 19.4%-52.6%];校正相对危险度2.3[95%CI 1.5-3.6];P<.001)。
  • 第24周11项报告次要终点中7项显示有利于托珠单抗的显著差异,包括平均CRP PMR-AS评分(7.5[95%CI 5.4-9.6] vs 14.9[95%CI 11.4-18.4];校正差值-7.5[95%CI -11.2至-3.8];P<.001)。
  • 不再接受泼尼松的患者百分比在托珠单抗组为49.0%,安慰剂组为19.6%(校正差值29.3%[95%CI 18.9%-39.7%];校正相对危险度2.5[95%CI 1.8-3.5];P<.001)。
  • 最常见不良事件为感染,托珠单抗组23例(46.9%)发生,安慰剂组20例(39.2%)发生。

关键数值与推荐

  • 主要疗效终点为第24周CRP PMR-AS<10(范围0-100,较高值表示活动度更高,未定义最小临床重要差异)且泼尼松剂量≤5 mg/日或较基线下降≥10 mg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要进一步研究以确认疗效并确定潜在获益与危害的平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Few treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active glucocorticoid-dependent polymyalgia rheumatica. OBJECTIVE: To compare the efficacy of tocilizumab vs placebo in patients with glucocorticoid-dependent polymyalgia rheumatica. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, parallel-group, placebo-controlled randomized clinical trial enrolled 101 patients with polymyalgia rheumatica at 17 hospitals in France from February 2017 to October 2019. Final follow-up occurred in November 2020. Inclusion criteria were persistent disease activity (polymyalgia rheumatica activity score computed using the C-reactive protein level [CRP PMR-AS] >10) and prednisone dose greater than or equal to 10 mg per day. INTERVENTIONS: Patients were randomly assigned to receive intravenous tocilizumab (8 mg/kg; n = 51) or placebo (n = 50) every 4 weeks for 24 weeks, combined with predefined standardized tapering of oral prednisone. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was CRP PMR-AS less than 10 (range, 0-100; higher values indicate greater activity; no minimal clinically important difference defined) combined with either prednisone dose less than or equal to 5 mg per day or a decrease in prednisone dose greater than or equal to 10 mg from baseline at week 24. There were 11 secondary outcomes assessed at week 24 included in this report, including disease activity (measured by CRP PMR-AS) and the proportion of patients no longer taking prednisone. RESULTS: Of the 101 randomized patients (mean age, 67.2 years; 68 [67.3%] women), 100 (99%) received at least 1 infusion and 100 completed the trial. The primary end point was achieved in 67.3% of patients in the tocilizumab group and 31.4% of patients in the placebo group (adjusted difference, 36.0% [95% CI, 19.4%-52.6%]; adjusted relative risk, 2.3 [95% CI, 1.5-3.6]; P < .001). Of 11 reported secondary end points at 24 weeks, 7 showed significant differences favoring tocilizumab, including mean CRP PMR-AS score (7.5 [95% CI, 5.4-9.6] vs 14.9 [95% CI, 11.4-18.4]; adjusted difference, -7.5 [95% CI, -11.2 to -3.8]; P < .001) and the percentage of patients no longer receiving prednisone (49.0% vs 19.6%; adjusted difference, 29.3% [95% CI, 18.9%-39.7%]; adjusted relative risk, 2.5 [95% CI, 1.8-3.5]; P < .001). The most frequent adverse events were infections, experienced by 23 patients (46.9%) in the tocilizumab group and 20 (39.2%) in the placebo group. CONCLUSIONS AND RELEVANCE: Among patients with active polymyalgia rheumatica despite prednisone therapy, tocilizumab, compared with placebo, resulted in a significantly greater percentage of patients with a CRP PMR-AS less than 10 with reduced prednisone requirements at week 24. Further research is needed to confirm efficacy and to determine the balance of potential benefits and harms. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02908217.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. JAMA. 2022. PMID: 36125471. doi:10.1001/jama.2022.15459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。